If you’re a foreign medical device manufacturer entering the U.S. market, FDA clearance and a distribution agreement are only part of the equation.

Depending on how your products are brought into the U.S. and commercialized, a U.S.-based party may meet the FDA’s definition of an initial importer—and take on important regulatory responsibilities as a result.

In practice, this role is often assigned based on convenience. A distributor, logistics partner, or U.S. contact is listed, and the business moves forward.

That approach can work—until a complaint arises, a regulatory question is raised, or expectations around reporting and documentation are tested.

In this post, I’ll walk through what an initial importer is, what the FDA expects from that role, and how the right partner can support and protect your business as you grow in the U.S. market.


What Is a U.S. Initial Importer?

The FDA defines an initial importer as a U.S.-based entity that:

While the definition is straightforward, the responsibilities tied to this role extend beyond logistics or sales.

Initial importers are subject to certain regulatory requirements under FDA regulations, which may include:

This places the initial importer within the postmarket regulatory framework, not just the commercial supply chain.


Why the Initial Importer Role Matters

When the role is not clearly defined or actively managed, gaps can develop—often without immediate visibility.

Common challenges include:

Unclear responsibility

Distributors, freight partners, and manufacturers may each assume that another party is handling regulatory obligations.

Missed or delayed complaint escalation

A concern raised by a hospital or clinic may be acknowledged operationally but not documented or evaluated in a way that meets FDA expectations.

Reactive compliance instead of proactive oversight

Registration details, complaint-handling processes, or reporting obligations may not be reviewed until an issue, audit, or customer inquiry triggers them.

I’ve seen situations where a complaint was received on the U.S. side, acknowledged informally, and never escalated through a structured process. By the time it was revisited, it was no longer an isolated issue—it was a pattern that required deeper review.

At that point, what could have been managed early becomes a broader regulatory and business concern.


What a Proactive Initial Importer Looks Like in Practice

A well-defined initial importer relationship provides more than a name on a registration. It creates a structured point of coordination within the U.S.

1. Structured complaint intake and escalation

Ensuring that complaints are received, documented, and communicated to the manufacturer in a way that supports timely evaluation and regulatory decision-making.

2. Alignment with FDA expectations

Supporting accurate registration and listing information, maintaining required records, and ensuring awareness of reporting obligations tied to U.S. distribution.

3. Reliable U.S.-based point of contact

Providing a consistent, professional presence for U.S. customers, distributors, and stakeholders who need a clear path for communication.

This does not replace the manufacturer’s regulatory responsibilities—it supports them with visibility and coordination at the U.S. level.


How the Right Initial Importer Supports Your Business

When approached intentionally, the initial importer role contributes to both compliance and commercial success.


What to Ask Before You Assign the Role

If you are determining who will serve as your U.S. initial importer, it is worth asking:

Clear, thoughtful answers to these questions are often a strong indicator of whether the role is being approached as a regulatory responsibility—or simply as an administrative step.


Final Thoughts

The initial importer may not be the most visible part of your U.S. strategy, but it is an important part of your regulatory foundation.

When the role is clearly defined and properly supported, it helps ensure that:

If your current setup was based on convenience rather than a clear understanding of responsibilities, it is worth taking a closer look—before that review is driven by a complaint, customer concern, or regulatory inquiry.


About the Author

Kristi Leigh
Smith Associates Imports, a division of Smith Associates

Kristi Leigh works with foreign medical device manufacturers to support U.S. market entry, including FDA initial importer responsibilities, import compliance, and ongoing regulatory coordination. Through Smith Associates Imports, a service line of Smith Associates, she helps bridge the gap between regulatory requirements and real-world execution—ensuring companies are positioned for both compliance and sustainable growth in the U.S. market.